Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy von Sherman, M, Yoshida, E M, Deschenes, M, Krajden, M, Bain, V G, Peltekian, K, Anderson, F, Kaita, K, Simonyi, S, Balshaw, R, Lee, S S

Volltext

Treating chronic hepatitis C with pegylated interferon alfa‐2a (40 KD) and ribavirin in clinical practice von LEE, S. S., BAIN, V. G., PELTEKIAN, K., KRAJDEN, M., YOSHIDA, E. M., DESCHENES, M., HEATHCOTE, J., BAILEY, R. J., SIMONYI, S., SHERMAN, M.

Volltext

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3 von Powis, J., Peltekian, K. M., Lee, S. S., Sherman, M., Bain, V. G., Cooper, C., Krajden, M., Deschenes, M., Balshaw, R. F., Heathcote, E. Jenny, Yoshida, E. M.

Volltext

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin von BAIN, V. G., LEE, S. S., PELTEKIAN, K., YOSHIDA, E. M., DESCHÊNES, M., SHERMAN, M., BAILEY, R., WITT‐SULLIVAN, H., BALSHAW, R., KRAJDEN, M.

Volltext

Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians von Cooper, Curtis L, Bailey, Robert J, Bain, Vince G, Anderson, Frank, Yoshida, Eric M, Krajden, Mel, Marotta, Paul

Volltext

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based... von Yoshida, Eric M, Sherman, Morris, Bain, Vincent G, Cooper, Curtis L, Deschênes, Marc, Marotta, Paul J, Lee, Samuel S, Krajden, Mel, Witt-Sullivan, Helga, Bailey, Robert J, Usaty, Christopher, Peltekian, Kevork, the Canadian Pegasys Study Group

Volltext

Identifying HCV genotype 1 patients at risk of relapse von Deschênes, Marc, Bain, Vincent G, Lee, Samuel S, Sherman, Morris, Cooper, Curtis L, Yoshida, Eric M, Marotta, Paul J, Krajden, Mel, Usaty, Christopher, Balshaw, Robert, Peltekian, Kevork M

Volltext

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin von Bain, V G, Lee, S S, Peltekian, K, Yoshida, E M, Deschênes, M, Sherman, M, Bailey, R, Witt-Sullivan, H, Balshaw, R, Krajden, M

Volltext